Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

ClinicalTrials.gov ID: NCT00839852

Public ClinicalTrials.gov record NCT00839852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.

Study identification

NCT ID
NCT00839852
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Forest Laboratories
Industry
Enrollment
97 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 61 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2009 (Actual)
Primary completion
Aug 31, 2010 (Actual)
Completion
Aug 31, 2010 (Actual)
Last update posted
Aug 22, 2019

2009 – 2010

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Forest Investigative Site Costa Mesa California 92626 —
Forest Investigative Site Long Beach California 90813 —
Forest Investigative Site Oceanside California 92056 —
Forest Investigative Site Paramount California 90723 —
Forest Investigative Site Riverside California 92506 —
Forest Investigative Site Washington D.C. District of Columbia 20016 —
Forest Investigative Site Bradenton Florida 34208 —
Forest Investigative Site Kissimmee Florida 34741 —
Forest Investigative Site Lake Charles Louisiana 70601 —
Forest Investigative Site Baltimore Maryland 21202 —
Forest Investigative Site Flowood Mississippi 39232 —
Forest Investigative Site Creve Coeur Missouri 63141 —
Forest Investigative Site Cincinnati Ohio 45267 —
Forest Investigative Site Charleston South Carolina 29405 —
Forest Investigative Site Memphis Tennessee 38119 —
Forest Investigative Site Houston Texas 77008 —
Forest Investigative Site Irving Texas 75062 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00839852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 22, 2019 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00839852 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →